<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03523338</url>
  </required_header>
  <id_info>
    <org_study_id>CR108434</org_study_id>
    <secondary_id>2017-004203-41</secondary_id>
    <secondary_id>56021927PCR3010</secondary_id>
    <nct_id>NCT03523338</nct_id>
  </id_info>
  <brief_title>An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer</brief_title>
  <official_title>An Open-Label Expanded Access Protocol for Apalutamide Treatment of Subjects With Non Metastatic Castration-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aragon Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aragon Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect additional safety data until apalutamide is
      commercially available for participants with non-metastatic castrate-resistant prostate
      cancer (NM-CRPC).
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Prostatic Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apalutamide</intervention_name>
    <description>Participants will receive apalutamide 240 mg orally once daily.</description>
    <other_name>JNJ-56021927</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADT (Standard of Care)</intervention_name>
    <description>Participants who did not undergo surgical castration, should receive and remain on a stable regimen of ADT according to local standard of care.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with confirmed prostate cancer, with evidence of castration resistance,
             with a rising prostate-specific antigen (PSA) while on androgen deprivation therapy
             (ADT), and for whom the treating physician believes additional therapy is indicated in
             the non-metastatic castrate-resistant prostate cancer (NM-CRPC) setting

             a) Willingness to continue gonadotropin releasing hormone analog (GnRHa) throughout
             study if the participant is medically castrated

          -  Must sign an informed consent form (ICF) (or the participant's legally acceptable
             representative must sign) indicating that the participant understands the purpose of,
             and procedures required for, the study and is willing to participate in the study

          -  To avoid risk of drug exposure through the ejaculate (even participants with
             vasectomies), participants must use a condom during sexual activity while on study
             drug and for 3 months following the last dose of study drug. Donation of sperm is not
             allowed while on study drug and for 3 months following the last dose of study drug

          -  Willingness and ability to comply with prohibitions and restrictions specified in this
             protocol, scheduled visits, treatment plans, laboratory, and other study procedures,
             including ability to swallow study drug tablets

        Exclusion Criteria:

          -  Previously enrolled in another apalutamide study or eligible for enrollment in another
             ongoing clinical study of apalutamide

          -  Enrolled in another interventional clinical study of anti-neoplastic agents

          -  Ongoing grade greater than (&gt;) 1 acute toxicity due to prior therapy or surgical
             procedure

          -  Concurrent therapy with medications known to lower the seizure threshold must have
             been discontinued or substituted at least 4 weeks prior to study entry

          -  Current or prior treatment with anti-epileptic medications for the treatment of
             seizures. History of seizure or condition that may predispose to seizure (including,
             but not limited to prior cerebrovascular accident, transient ischemic attack, or loss
             of consciousness within 1 year prior to randomization; brain arteriovenous
             malformation; or intracranial masses such as a schwannoma or meningioma that is
             causing edema or mass effect)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aragon Pharmaceuticals, Inc. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Aragon Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ynova Pesquisa Clinica</name>
      <address>
        <city>Florianopolis</city>
        <zip>88020-210</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Instituto COI de Pesquisa, Educacao e Gestao</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>22793-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Instituto Etica - Amo</name>
      <address>
        <city>Salvador</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>ICESP - INSTITUTO DO CANCER DO ESTADO DE SAO PAULO OCTAVIO FRIAS de OLIVEIRA</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01246-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Fundacao Antonio Prudente</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01509900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>IBCC Instituto Brasileiro de Controle do Cancer</name>
      <address>
        <city>Sao Paulo</city>
        <zip>03102-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria Colombia</name>
      <address>
        <city>Bogota</city>
        <zip>0000</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Fundacion Santa Fe de Bogota</name>
      <address>
        <city>Bogotá</city>
        <zip>110111</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Ignacio</name>
      <address>
        <city>Bogotá</city>
        <zip>110231</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerologia</name>
      <address>
        <city>Bogotá</city>
        <zip>111511</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo Tobón Uribe</name>
      <address>
        <city>Medellín</city>
        <zip>050034</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Centro Medco ABC Observatorio</name>
      <address>
        <city>Ciudad de México</city>
        <zip>01120</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Inst. Nal. de Ciencias Med. Y Nutricion Salvador Zubiran</name>
      <address>
        <city>Mexico City</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Centro Medico Nacional 20 de Noviembre ISSSTE</name>
      <address>
        <city>Mexico City</city>
        <zip>3229</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerologia</name>
      <address>
        <city>Mexico</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Hospital Central Sur de Alta Especialidad Pemex Picacho</name>
      <address>
        <city>Mexico</city>
        <zip>14140</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>i Can Oncology Center</name>
      <address>
        <city>Monterrey</city>
        <zip>64710</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Oncología Integral Satelite</name>
      <address>
        <city>Naucalpan</city>
        <zip>53100</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Estatal ISSEMYM</name>
      <address>
        <city>Toluca</city>
        <zip>50180</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Farmaco Oncología especializada S.A. de C.V</name>
      <address>
        <city>Zapopan</city>
        <zip>45050</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108434</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 1, 2018</study_first_submitted>
  <study_first_submitted_qc>May 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2018</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

